12 IPOs Planned for February 3 Week

Francis Gaskins  |

The full IPO calendar is available at IPOpremium.com

Ranked by size of IPO, largest first.

(1) Real estate finance

Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the NYSE with a market capitalization of $1.7 billion at a price range midpoint of $17 for Friday, February 7, 2014.

A commercial finance company, LADR conducts its business through three major business lines: commercial mortgage lending, investments in securities secured by first mortgage loans, and investments in selected net leased and other commercial real estate assets.

(2) Gypsum wallboard mfg

Based in Reston, VA, Continental Building Products ($CBPX) scheduled a $225 million IPO on the NYSE with a market capitalization of $750 million at a price range midpoint of $17 for Wednesday, February 5, 2014.

According to CBPX the company is a leading, high margin manufacturer of gypsum wallboard and complementary finishing products.

(3) Closed end fund

Based in New York, NY, CM Finance ($CMFN) scheduled a $100 million IPO on the Nasdaq with a market capitalization of $190 million at a price range midpoint of $15 for Thursday, February 6, 2014.

CMFN is a specialty finance company that invests primarily in the debt of middle-market companies.  Expects to pay a 9% dividend.

(4) Biopharma

Based in Newark, CA, Revance Therapeutics ($RVNC) scheduled a $75 million IPO on the Nasdaq with a market capitalization of $253 million at a price range midpoint of $15 for Thursday, February 6, 2014.

RVNC is working on providing Botox benefits without injections, by just rubbing RVNC’s product on the skin.

(5) Biotech

Based in Cambridge, MA, Genocea Biosciences ($GNCA) scheduled a $72 million IPO on the Nasdaq with a market capitalization of $224 million at a price range midpoint of $13 for Wednesday, February 5, 2014.

GNCA is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.

(6) Gene therapy

Based in Amsterdam, Netherlands,uniQure ($QURE) scheduled a $64 million IPO on the Nasdaq with a market capitalization of $235 million at a price range midpoint of $235 for Wednesday, February 5, 2014.

QURE is a leader in the field of gene therapy and has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union.

(7) Biopharma

Based in San Diego, CA, Auspex Pharmaceuticals ($ASPX) scheduled a $61 million IPO on the Nasdaq with a market capitalization of $231 million at a price range midpoint of $11 for Wednesday, February 5, 2014.

ASPX is a biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of orphan diseases.

(8) Biopharma

Based in Cambridge, MA, Eleven Biotherapeutics ($EBIO) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $206 million at a price range midpoint of $14 for Thursday, Feb. 6, 2014.

EBIO is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye.

(9) Biopharma

Based in Durham, NC, Argos Therapeutics ($ARGS) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $247 million at a price range midpoint of $14 for Friday, February 7, 2014.

ARGS is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.

(10) Specialty pharma

Based in Malvern, PA, Egalet ($EGLT) scheduled a $42 million IPO on the Nasdaq with a market capitalization of $167 million at a price range midpoint of $12 for Friday, February 7, 2014.

EGLT’s lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain.

(11) Pharma

Based in Research Triangle Park, NC, NephroGenex ($NRX) scheduled a $40 million IPO on the Nasdaq with a market capitalization of $40 million at a price range midpoint of $13 for Friday, February 7, 2014.

NRX is a pharmaceutical company focused on the development of therapeutics to treat kidney disease, an area of significant unmet medical need.

(12)  Cancer diagnostics

Based in San Diego, CA, Biocept ($BIOC) scheduled a $20 million IPO on the Nasdaq with a market capitalization of $52 million at a price range midpoint of $11 for Wednesday, February 5, 2014.

BIOC is an early-stage cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
LADR Ladder Capital Corp Class A 17.06 -0.20 -1.16 924,162 Trade
GNCA Genocea Biosciences Inc. 0.55 -0.01 -2.42 159,730 Trade
CBPX Continental Building Products Inc. 25.86 0.18 0.70 438,686 Trade
RVNC Revance Therapeutics Inc. 19.91 -0.79 -3.82 321,672 Trade
EBIO SESN Eleven Biotherapeutics Inc. n/a n/a n/a n/a
BIOC Biocept Inc. 0.82 0.05 6.14 353,811 Trade
QURE uniQure N.V. 28.14 -0.15 -0.53 278,037 Trade
NRX NephroGenex Inc n/a n/a n/a n/a
DLKGF Delek Group Ltd 125.07 0.00 0.00 0

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd through its subsidiary operates as a cannabinoid-based research and development company in Canada.